Digital Public Defence: Mohammad Osman Pervez Mohammad Osman Pervez at Institute of Clinical Medicine will be defending the thesis “Novel biomarkers in patients with acute dyspnea” for the degree of PhD (Philosophiae Doctor).

Image may contain: Glasses.

The public defence will be held as a video conference over Zoom.

The defence will follow regular procedure as far as possible, hence it will be open to the public and the audience can ask ex auditorio questions when invited to do so.


Click here to participate in the digital trial lecture

Download Zoom here


Digital Trial Lecture – time and place

See Digital Trial Lecture.

Adjudication committee

  • First opponent: Associate professor Martin Magnusson, Lunds Universitet
  • Second opponent: Professor Rune Wiseth, NTNU
  • Third member and chair of the evaluation committee: Professor Anne Eskild, University of Oslo

Chair of the Defence

Professor Vegard Dahl, University of Oslo

Principal Supervisor

Researcher Helge Røsjø, University of Oslo


Patients with acute dyspnea represent a medical emergency, frequently caused by heart failure (HF) or chronic obstructive pulmonary disease (COPD), conditions associated with significant mortality. With an aging population, the prevalence of HF will increase.

Several pathophysiological pathways are activated in HF and can be monitored by cardiovascular (CV) biomarkers. Novel biomarkers may therefore improve the management of patients with acute dyspnea. Hence, Mohammad Osman Pervez, MD, and colleagues have assessed the potential of three novel CV biomarkers in patients with dyspnea included in the ACE 2 Study.

In paper #1, tMR-proADM measured <24 h of admission was inferior to NT-proBNP to diagnose acute HF. However, elevated concentrations of MR-proADM were strongly associated with mortality after adjusting for established risk factors. In paper #2, we found MR-proANP to demonstrate similar diagnostic and prognostic accuracy as NT-proBNP in patients with acute dyspnea. In contrast to NT-proBNP, MR-proANP was also indpendently associated with mortality in patients with acute COPD. FGF23 is known to predict outcome in patients with chronic renal failure, a common comorbidity in patients with HF. We are the first to examine FGF23 in patients with acute dyspnea, regardless of their renal funtion. In paper #3, FGF23 measured <24 h of admission independently predicted poor outcome in adjusted risk models. However, FGF23 was inferior to NT-proBNP for diagnosing HF and for risk assessment in patients with HF.

In paper #4, we provide the rationale and methodology for the ACE 1950 Study which is a large community-acquired cohort. Dr. Pervez and co-workers examined 3706 participants with extensive phenotyping at the baseline visit, and are permitted follow these participants until year 2050.The ACE 1950 Study will generate new knowledge related to patients with dyspnea, and especially HF.

Additional information

Contact the research support staff.



Published Aug. 27, 2020 10:34 AM - Last modified Sep. 11, 2020 1:00 PM